

IN VITRO FERTILISATION UK MARKET REPORT

FIRST EDITION

ORDER THE REPORT TODAY

£850 Single-user Printed Hard Copy

£2,125 Multi-user Digital PDF
+ VAT + Data in Excel



Digital reports include print copy back-up as well as PDF and Excel spreadsheet including all data and charts, with licence allowing multi-reader access across your organisation. Licence includes the reasonable use of LaingBuisson data within your own reports.

Who is the report for

- C-suite professionals working in international fertility treatment groups
- C-suite professionals working in private hospital groups
- Clinic owners
- NHS commissioners
- NHS acute trusts involved in or considering providing fertility services
- Banks and other financial institutions
- Investors and private equity
- Insurers
- National government policy-makers
- Lawyers
- Policy advisors
- Think tanks
- Management consultants

Dynamic and innovative – growth is accelerating in the UK IVF market

The UK market for fertility treatment (principally in vitro fertilisation (IVF) but also intra uterine insemination (IUI)) is experiencing accelerating growth, with volumes growing by around 3% per year. Key drivers currently include the greater acceptability of IVF as a route to having a family, especially as the number of people delaying starting a family is rising and more same-sex couples opt to have families. Success rates, which have improved by a factor of 2.5x since 1991, are also encouraging more childless people to turn to IVF.

As of 2016, the market was worth £320m, made up of 68,000 IVF cycles and 13,500 IUI cycles. The market is served by 82 fertility clinics and 30 satellite clinics, making it fragmented and the largest groups account for less than 25% of the cycles. While major hospital groups such as HCA, BMI and Nuffield are involved in the market, they do not seem to be growing their presence.



There remain also a large number of owner-managed clinics, many of which were established in the high-growth years of the mid-1990s, meaning that some owners may be considering exiting. This offers opportunities for would-be investors.

Future growth is likely to be fuelled by further innovation. Clinics and clinicians are always looking for ways of improving their success rates and to add value for their clients. Innovations in genetic testing are reducing the risk of passing on inherited diseases, yet pre-implantation genetic diagnostics still only account for around 1% of IVF cycles. Also, by international standards, the UK has low treatment rates pointing to scope for future growth as confidence in IVF, its success rates and benefits increases.

LaingBuisson will hold its first **Fertility Forum** on Friday 2 November, ahead of the Fertility Show at London Olympia on 3-4 November. This one-day conference will enable providers, patients and professional associations in this dynamic market to share knowledge, experience and insight. For more details, see our dedicated website www.fertility-forum.com

What the report includes

Market
Definition
Size
Segmentation
Funding
Supply and Demand
Drivers of demand
Business models
Operational statistics
Performance measures
Government Policy and Regulation
Payors
Major Providers
Investors
Market Potential

Appendices
The Process of IVF
CCG Funded Cycles
Regulators
Professional and Patient Associations
Financial Appendix

Visit laingbuisson.com to find out more and to download full contents and figures listings